By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – South Korean life sciences company Chemizon, a division of Optomagic, said today that it will support Shenogen Pharma Group's drug development programs aimed at developing small molecule therapeutics for cancer and endocrine disorders.

Chemizon will be responsible for a range of services and activities, including lead optimization, assay development, computational chemistry, animal pharmacology, and absorption, distribution, metabolism, and excretion processes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.